Navigation Links
PROLOR Biotech Announces Presentation of Data on Its Long-Acting Clotting Factors at World Federation of Hemophilia World Congress
Date:7/10/2012

mmercial products, including any long-acting versions of human growth hormone, erythropoietin, interferon beta, GLP-1 and other products; that the long-acting products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; that the actual dollar amount of any grants from Israel's Office of the Chief Scientist is uncertain and is subject to policy changes of the Israeli government, and that such grants may be insufficient to assist with product development; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the CTP platform technology could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties.  In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in PROLOR's filings with the Securities and Exchange Commission.  The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required u
'/>"/>
SOURCE PROLOR Biotech, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Data From Phase II Trial of Prolor Biotechs Long-acting Human Growth Hormone Presented at Endo 2012
2. GenWay Biotech Launches New Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 2011
3. Puma Biotechnology Announces Completion of Private Placement
4. Animal Biotechnology - Technologies, Markets and Companies
5. AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug
6. The European Union Signs Grant Contract to Fund a 2 Million Euro Biotechnology Research Project Led by Hadassah College Jerusalem
7. Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765
8. Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium
9. Metamark Genetics Signs Collaboration Agreement on Novel Therapeutic Targets with Janssen Biotech
10. SuperNova Diagnostics® to Present at Biotech Showcase™ 2012 During JP Morgan Healthcare Conference January 9 - 12
11. Saladax Biomedical, Inc. to Present at Biotech Showcase™ 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Fla. , Sept. 2, 2014  Technology Applications ... announced that its wholly-owned subsidiary Renuell Int,l, Inc. has ... Aeronautics and Space Administration ("NASA") at the Johnson Space ... See photos: tapplic.com/houstonphotos/ ... "We are very pleased to announce our latest, exclusive ...
(Date:9/2/2014)... Philadelphia, PA (PRWEB) September 02, 2014 ... pioneered a new highly efficient, cost effective approach ... U.S. Patent No. 8,820,265 by the U.S. Patent ... proprietary to Opertech. , “Opertech’s taste ... is the first automated high throughput system for ...
(Date:9/2/2014)... Sept. 2, 2014  Xencor, Inc. (NASDAQ: ... engineered monoclonal antibodies for the treatment of autoimmune ... announced the appointment of Debra Zack , ... appointment of Lloyd Rowland , senior vice ... "Debra,s expertise in biologics clinical development ...
(Date:9/2/2014)...  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... targeting specific pathogens that cause serious infections and ... preclinical toxicology study of SYN-004. Per U.S. Food ... was required to move the Company,s lead anti-infective, ... effects of Clostridium difficile (C. difficile), ...
Breaking Biology Technology:Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 2Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 3Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5
... ArunA Biomedical, Inc., the first,company to commercialize human ... that William T. Sharp has been named President,and ... leadership,responsibilities, Mr. Sharp has also been appointed to ... Steven Stice, PhD, who will,remain ArunA,s Chairman and ...
... July 29 Xceed,Molecular, a pioneer in the ... its new Inflammation Xpress,Chip, a pre-configured array for ... at the 2008 AACC/ASCLS Clinical Lab Expo,(booth 2155). ... E. Washington,Convention Center in Washington, DC., "With ...
... are everywhere from the air we breathe and the food ... are innocuous or even beneficial, and only a handful pose any ... unwanted intruder? , Research from the University of Wisconsin-Madison suggests ... , A study appearing online this week in the Proceedings ...
Cached Biology Technology:ArunA Biomedical Names William T. Sharp President and Chief Executive Officer 2Xceed Molecular to Launch New Inflammation Xpress Chip(TM)for the Ziplex(R) Automated Gene-Expression Analysis System at Clinical Lab Expo 2008, Booth 2155 2Xceed Molecular to Launch New Inflammation Xpress Chip(TM)for the Ziplex(R) Automated Gene-Expression Analysis System at Clinical Lab Expo 2008, Booth 2155 3Symbiotic microbes induce profound genetic changes in their hosts 2
(Date:9/2/2014)... integrity? Tell the truth; everyone has a tipping point. We ... lie if the benefit is great enough. Now, scientists have ... that decision. , The result was published online this ... prefer to be honest, even if lying is beneficial," said ... at the Virginia Tech Carilion Research Institute , where ...
(Date:9/2/2014)... in Taiyuan, China, have substantially improved the health of ... reduction in costs associated with loss of life and ... the Columbia Center for Children,s Environmental Health (CCCEH) at ... University, the Center of Diseases Control and Prevention of ... Health. , The study is the first to document ...
(Date:9/2/2014)... When you accidentally touch a hot oven, you rapidly ... neural circuits involved in sensing and responding to such ... players. , Duke researchers have made a surprising discovery ... pain in worms, and have built a structural model ... Nature Communications , may help direct new strategies ...
Breaking Biology News(10 mins):Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 2Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 3Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 4Clean air halves health costs in Chinese city 2Surprising new role for calcium in sensing pain 2Surprising new role for calcium in sensing pain 3
... Local and regional researchers collect large amounts of ... but the researchers that create the economic and climate ... Now, thanks to a $2 million grant from the ... the modelers through the Penn State Institutes of Energy ...
... in Spanish . Wheat growers in ... to climate change in the decades ahead, thanks to U.S. ... with the USDA,s Agricultural Research Service (ARS) installed infrared heaters ... Center in Maricopa, Ariz., to simulate growing conditions expected by ...
... the recent prediction that half of all Americans will have ... a new genetic discovery published online in the FASEB ... to why: we took an evolutionary "wrong turn." In the ... loss of function in a gene called "CMAH" may make ...
Cached Biology News:DOE grant joins climate modeling with local, regional empirical data 2Examining climate change effects on wheat 2New research suggests that obesity and diabetes are a downside of human evolution 2